IN2012DN03129A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03129A IN2012DN03129A IN3129DEN2012A IN2012DN03129A IN 2012DN03129 A IN2012DN03129 A IN 2012DN03129A IN 3129DEN2012 A IN3129DEN2012 A IN 3129DEN2012A IN 2012DN03129 A IN2012DN03129 A IN 2012DN03129A
- Authority
- IN
- India
- Prior art keywords
- group
- optionally substituted
- cis
- indistinctly
- atom
- Prior art date
Links
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382193A EP2305643A1 (en) | 2009-10-02 | 2009-10-02 | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers |
| PCT/EP2010/064653 WO2011039353A1 (en) | 2009-10-02 | 2010-10-01 | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03129A true IN2012DN03129A (enrdf_load_stackoverflow) | 2015-09-18 |
Family
ID=41716282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3129DEN2012 IN2012DN03129A (enrdf_load_stackoverflow) | 2009-10-02 | 2010-10-01 |
Country Status (16)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9085570B2 (en) * | 2010-10-11 | 2015-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Substituted benzamides and their uses |
| AU2014260605B2 (en) | 2013-04-29 | 2016-07-14 | Chong Kun Dang Pharmaceutical Corp. | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same |
| ES2770123T3 (es) | 2015-02-02 | 2020-06-30 | Forma Therapeutics Inc | Acidos 3-alquil-4-amido-bicíclicos [4,5,0]hidroxámicos como inhibidores de HDAC |
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| WO2017029684A1 (en) * | 2015-08-17 | 2017-02-23 | University Of Mysore | 2,3,5 trisubstituted pyrrole derivatives as topoisomerase inhibitors and therapeutic uses thereof |
| WO2017218950A1 (en) | 2016-06-17 | 2017-12-21 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| CN107793375A (zh) * | 2016-08-31 | 2018-03-13 | 中国科学院上海药物研究所 | 一类芳基2,2’‑串联双噻唑类化合物及其制备方法和用途 |
| EP3318256A1 (en) * | 2016-11-08 | 2018-05-09 | Quimatryx, S.L | Compounds for the treatment of autoimmune diseases |
| GB201708457D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Inhibitors of metallo-beta-lactamases |
| CN110938055A (zh) * | 2018-09-21 | 2020-03-31 | 华东师范大学 | 六元环甲酰胺类化合物及其合成方法和应用 |
| CA3137054A1 (en) | 2019-04-17 | 2020-10-22 | Quimatryx, S.L. | 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors |
| CN112516142B (zh) * | 2020-12-11 | 2021-10-15 | 北京华氏精恒医药科技有限公司 | 一种具有hdac抑制活性的药物组合物、制备方法及其用途 |
| CN112225737B (zh) * | 2020-12-11 | 2021-04-09 | 北京鑫开元医药科技有限公司 | 具有hdac抑制活性的化合物、制备方法、组合物及用途 |
| CN116813560A (zh) * | 2022-03-28 | 2023-09-29 | 上海科技大学 | 三唑酰胺类化合物及其制备方法和用途 |
| CN114558004B (zh) | 2022-03-29 | 2023-08-11 | 奎马特里克斯有限公司 | Qtx125药物制剂 |
| CN114634489B (zh) * | 2022-04-19 | 2023-07-04 | 奎马特里克斯有限公司 | 结晶形式 |
| CN114652715B (zh) * | 2022-04-29 | 2023-04-25 | 奎马特里克斯有限公司 | 联合疗法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| US7781595B2 (en) | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
| MXPA06005915A (es) * | 2003-12-05 | 2006-06-27 | Warner Lambert Co | N-alquil pirroles como inhibidores de la hmg-coa reductasa. |
| WO2006108864A2 (en) * | 2005-04-15 | 2006-10-19 | Dominion Pharmakine S.L. | New nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof |
| US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| JP4975758B2 (ja) * | 2005-12-27 | 2012-07-11 | ウニベルシダッド、デル、パイス、バスコ‐エウスカル、エリコ、ウニベルトシタテア、（ウペウベ‐エアチェウ） | ヒストンデアセチラーゼ阻害活性を有する新規ピロール誘導体 |
| US8673911B2 (en) * | 2007-11-02 | 2014-03-18 | Methylgene Inc. | Inhibitors of histone deacetylase |
-
2009
- 2009-10-02 EP EP09382193A patent/EP2305643A1/en not_active Withdrawn
-
2010
- 2010-10-01 RU RU2012117885/04A patent/RU2549885C2/ru not_active IP Right Cessation
- 2010-10-01 AU AU2010302572A patent/AU2010302572B2/en active Active
- 2010-10-01 JP JP2012531445A patent/JP5746185B2/ja active Active
- 2010-10-01 CN CN201080052814.XA patent/CN102648177B/zh active Active
- 2010-10-01 PT PT107636763T patent/PT2483242E/pt unknown
- 2010-10-01 US US13/499,839 patent/US8685992B2/en active Active
- 2010-10-01 BR BR112012007411A patent/BR112012007411B8/pt active IP Right Grant
- 2010-10-01 CA CA2776351A patent/CA2776351C/en active Active
- 2010-10-01 MX MX2012003988A patent/MX2012003988A/es active IP Right Grant
- 2010-10-01 EP EP10763676.3A patent/EP2483242B1/en active Active
- 2010-10-01 ES ES10763676.3T patent/ES2452868T3/es active Active
- 2010-10-01 IN IN3129DEN2012 patent/IN2012DN03129A/en unknown
- 2010-10-01 KR KR1020127011407A patent/KR101754940B1/ko active Active
- 2010-10-01 PL PL10763676T patent/PL2483242T3/pl unknown
- 2010-10-01 WO PCT/EP2010/064653 patent/WO2011039353A1/en active Application Filing
-
2012
- 2012-04-02 IL IL218995A patent/IL218995A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2452868T3 (es) | 2014-04-03 |
| CA2776351A1 (en) | 2011-04-07 |
| PL2483242T3 (pl) | 2014-05-30 |
| US8685992B2 (en) | 2014-04-01 |
| HK1173450A1 (en) | 2013-05-16 |
| US20120196885A1 (en) | 2012-08-02 |
| KR101754940B1 (ko) | 2017-07-06 |
| IL218995A0 (en) | 2012-06-28 |
| CN102648177A (zh) | 2012-08-22 |
| EP2483242A1 (en) | 2012-08-08 |
| RU2012117885A (ru) | 2013-11-10 |
| AU2010302572A8 (en) | 2012-05-24 |
| PT2483242E (pt) | 2014-03-17 |
| RU2549885C2 (ru) | 2015-05-10 |
| AU2010302572B2 (en) | 2016-10-20 |
| BR112012007411A2 (pt) | 2016-12-06 |
| KR20120091176A (ko) | 2012-08-17 |
| EP2483242B1 (en) | 2013-12-11 |
| CN102648177B (zh) | 2015-01-07 |
| AU2010302572A1 (en) | 2012-05-17 |
| JP5746185B2 (ja) | 2015-07-08 |
| BR112012007411B8 (pt) | 2021-05-25 |
| CA2776351C (en) | 2017-10-31 |
| BR112012007411B1 (pt) | 2020-12-15 |
| MX2012003988A (es) | 2012-07-23 |
| JP2013506637A (ja) | 2013-02-28 |
| WO2011039353A1 (en) | 2011-04-07 |
| IL218995A (en) | 2016-11-30 |
| EP2305643A1 (en) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03129A (enrdf_load_stackoverflow) | ||
| PH12012501029A1 (en) | Spiroindolinone pyrrolidines | |
| MX2011008176A (es) | Derivados de 3,3'-espiroindolinona como agentes anticancerigenos. | |
| CR11150A (es) | Compuestos de bencimidazol | |
| PH12012501711A1 (en) | [5,6] heterocyclic compound | |
| MX341133B (es) | Compuestos y metodos para la inhibición de hdac. | |
| PH12012500634A1 (en) | Processes for preparing of glucopyranosyl -substituted benzyl -benzene derivatives | |
| MX337714B (es) | Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk). | |
| PH12012501650B1 (en) | Heterocyclic compound | |
| MX2010004493A (es) | Compuestos de tropano. | |
| NZ592497A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| PH12012501546A1 (en) | Substituted pyrrolidine-2-carboxamides | |
| AU2008303600A8 (en) | 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives | |
| MY193277A (en) | Certain amino-pyrimidines, compositions thereof, and methods for their use | |
| MY160424A (en) | Substituted pyrrolidine-2-carboxyamides. | |
| MX2012006805A (es) | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa. | |
| WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
| IN2012DN02487A (enrdf_load_stackoverflow) | ||
| MX2009003081A (es) | Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas. | |
| MX2011007886A (es) | Derivado de espiroindolinona piridina. | |
| MX2012007835A (es) | Derivados de oxazolopirimidina sustituida en 2, 5,7. | |
| IN2014CN04449A (enrdf_load_stackoverflow) | ||
| NZ597916A (en) | Benzoquinolizinium salt derivatives as anticancer agents | |
| GB2470170A (en) | Dithienothiophene derivatives | |
| PH12013500443A1 (en) | Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine. |